# Towards a clinically practical computational platform for systematically adapting radiation therapy for glioma patients.

- **DOI:** [10.1088/1361-6560/ae9687](https://doi.org/10.1088/1361-6560/ae9687)
- **Rating:** Sound (3.3 out of 5)
- **Verdict:** An integrated adaptive-radiotherapy pipeline predicts better glioma control and demonstrates partial planning feasibility, but its benefits remain unvalidated model outputs.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-01
- **Evaluation page:** https://www.nabu.science/paper/10.1088%2F1361-6560%2Fae9687

## Key claims

1. Our adaptation pipeline predicted a median (range) decrease in tumor burden of 31% (12% and 57%) one month post-therapy across the patient cohort compared to the SOC predicted tumor burden (p< 0.05).
   - Support: Tentative
   - Type: Primary finding
   - Basis: counterfactual model forecasts without observed outcomes, with statistical reporting and voxel-dependence concerns
   - Location: Abstract, Main results; Results, Figure 4
2. After adjusting the dose plan for clinical deliverability, it still predicted a decrease in tumor burden of 30% (7% and 62%) which is also significantly different than the SOC protocol (p< 0.05).
   - Support: Tentative
   - Type: Secondary
   - Basis: model-only deliverability comparison with incomplete clinical constraints and a 62%-versus-53% reporting discrepancy
   - Location: Abstract, Main results; Results, Figure 4
3. The homogeneous dose boost led to a predicted median decrease of 11% (interquartile range: 14%) compared to the 31% obtained with the in silico dose-adapted map.
   - Support: Supported
   - Type: Secondary
   - Basis: same-total-dose model comparison supports spatial targeting within this cohort but not a definitive clinical advantage
   - Location: Results, paragraph following Figure 4; Supplementary Figure S3

## Strengths

- **Integrated imaging-to-planning adaptation workflow** The study links mid-treatment cellularity changes to spatial dose adaptation, mechanistic forecasting, and reconstruction in a clinical treatment-planning system.
  - Dimension: contribution
  - Location: Introduction, final paragraph; Methods, Dose Map Adaptation and Physical Deliverability
- **Comparators isolate spatial targeting value** SOC is supplemented by a same-total-dose homogeneous boost, while additional boost levels test the model’s dose response. These analyses separate spatial targeting from dose escalation alone.
  - Dimension: methodological rigour
  - Location: Results, Figure 4 and Supplementary Figures S3–S4
- **Limitations tied to clinical consequences** The Discussion connects supratypical fraction sizes, organ-at-risk constraints, multileaf-collimator resolution, and ring-shaped targets to safety and deliverability requirements.
  - Dimension: positioning
  - Location: Discussion, paragraphs 4–6; Figure 5

## Limitations

- **Clinical benefit remains entirely model-predicted** No patient received an adapted plan, so the reported tumor-burden reductions do not establish effects on observed tumor control, toxicity, or survival.
  - Dimension: methodological rigour
  - Location: Abstract, Approach and Main Results; Discussion, paragraph 6
- **Statistical reporting and dependence concerns** Methods specify Mann–Whitney tests over spatially correlated voxels, while Results add Wilcoxon and patient-level bootstrap analyses not described there. The clinically deliverable range also differs between the Abstract and Results.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Test and Confidence Intervals; Abstract, Main Results; Results, Figure 4
- **Deliverability omits clinical planning constraints** The optimizer did not incorporate organs at risk, target coverage, conformity, homogeneity, or quantitative failure criteria, limiting the meaning of “clinically deliverable.”
  - Dimension: application pathway
  - Location: Methods, Physical Deliverability; Discussion, paragraph 6

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The direction and medians of the main findings are consistent, but the paper contains reporting and inferential mismatches that complicate interpretation of statistical significance. These concerns do not reverse the cohort-level model result.
- **Research conduct:** Clean. Ethics approval and a retrospective informed-consent waiver are declared, and the restricted data-access statement is consistent with sensitive clinical data. Lack of public code and an explicit conflict-of-interest statement limits transparency but does not establish a conduct concern.
- **Reference integrity:** Clean. 42 of 42 checkable references verified
  - 42 references in manuscript
  - citation details diverge from the cited records for 3 references
  - Citation details diverge for 3 references:
    - #16 Jarrett A M 2020 Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data Neoplasia 22 820 30 820–30 10.1016/j.neo.2020.09.004 33197744 PMC7677708 (Differs from the cited DOI’s record on: title, authors)
    - #21 Lorenzo G Heiselman J S Liss M A Miga M I Gomez H Yankeelov T E Reali A Hughes T J R 2024 A pilot study on patient-specific computational forecasting of prostate cancer growth during active surveillance using an imaging-informed biomechanistic model Cancer Res. Commun. 4 617 33 617–33 10.1158/2767-9764.CRC-23-0192 38426815 PMC10906139 (Differs from the cited DOI’s record on: title, authors)
    - #32 Qi X S Schultz C J Li X A 2006 An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumors Int. J. Radiat. Oncol. Biol. Phys. 64 1570 80 1570–80 10.1016/j.ijrobp.2005.11.038 16580506 (Differs from the cited DOI’s record on: title, authors)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
